Cargando…
Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors
HIV-1 maturation inhibitors (MIs) disrupt the final step in the HIV-1 protease-mediated cleavage of the Gag polyprotein between capsid p24 capsid (CA) and spacer peptide 1 (SP1), leading to the production of infectious virus. BMS-955176 is a second generation MI with improved antiviral activity towa...
Autores principales: | Lin, Zeyu, Cantone, Joseph, Lu, Hao, Nowicka-Sans, Beata, Protack, Tricia, Yuan, Tian, Yang, Hong, Liu, Zheng, Drexler, Dieter, Regueiro-Ren, Alicia, Meanwell, Nicholas A., Cockett, Mark, Krystal, Mark, Lataillade, Max, Dicker, Ira B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125710/ https://www.ncbi.nlm.nih.gov/pubmed/27893830 http://dx.doi.org/10.1371/journal.ppat.1005990 |
Ejemplares similares
-
GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022) -
Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage
por: Nowicka-Sans, Beata, et al.
Publicado: (2016) -
The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates
por: Ray, Neelanjana, et al.
Publicado: (2017) -
Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
por: Dicker, Ira, et al.
Publicado: (2019) -
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)